Clovis Oncology Analyst Ratings
Clovis Oncology Analyst Ratings
While ratings are subjective and will change, the latest Clovis Oncology (CLVS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clovis Oncology (CLVS) is trading at is $0.28, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 05/06/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/05/2022 | 1338.33% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 09/21/2021 | 3136.25% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 08/05/2021 | 3495.83% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/05/2021 | 4214.99% | HC Wainwright & Co. | $13 → $12 | Maintains | Buy |
| 11/06/2020 | 978.75% | SVB Leerink | $4 → $3 | Maintains | Underperform |
| 11/06/2020 | 5293.74% | HC Wainwright & Co. | $23 → $15 | Maintains | Buy |
| 05/22/2020 | 10327.9% | HC Wainwright & Co. | $33 → $29 | Reiterates | → Buy |
| 05/20/2020 | 1338.33% | SVB Leerink | $5 → $4 | Maintains | Underperform |
| 05/18/2020 | 11766.24% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 05/06/2020 | 10327.9% | HC Wainwright & Co. | $27 → $29 | Reiterates | → Buy |
| 04/27/2020 | 1697.91% | SVB Leerink | → $5 | Downgrades | Market Perform → Underperform |
| 04/09/2020 | 2057.5% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 01/23/2020 | 3495.83% | B of A Securities | $7 → $10 | Maintains | Neutral |
| 11/19/2019 | 2776.66% | Evercore ISI Group | → $8 | Downgrades | Outperform → In-Line |
| 10/08/2019 | 978.75% | Goldman Sachs | $13 → $3 | Maintains | Sell |
| 09/24/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 08/13/2019 | 2417.08% | B of A Securities | $13 → $7 | Downgrades | Buy → Neutral |
| 08/02/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 05/29/2019 | 5293.74% | Goldman Sachs | $17 → $15 | Downgrades | Neutral → Sell |
| 02/13/2019 | 14283.32% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 10/31/2018 | 14283.32% | Barclays | $58 → $40 | Maintains | Overweight |
| 10/31/2018 | 5653.33% | JP Morgan | $71 → $16 | Downgrades | Overweight → Neutral |
| 09/25/2018 | 10687.49% | Leerink Swann | → $30 | Initiates Coverage On | → Market Perform |
| 02/27/2018 | 30464.55% | Barclays | $105 → $85 | Maintains | Overweight |
| 02/27/2018 | 39454.12% | Stifel | $125 → $110 | Maintains | Buy |
| 02/22/2018 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 02/22/2018 | — | RBC Capital | Upgrades | Sector Perform → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 10 月 11 日 | — | 摩根大通 | 降级 | 中性 → 体重不足 | |
| 2022 年 6 月 5 日 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 05/05/2022 | 1338.33% | HC Wainwright & Co. | 5 美元 → 4 美元 | 维护 | 买 |
| 09/21/2021 | 3136.25% | HC Wainwright & Co. | 10 美元 → 9 美元 | 维护 | 买 |
| 08/05/2021 | 3495.83% | HC Wainwright & Co. | 12 美元 → 10 美元 | 维护 | 买 |
| 2021 年 5 月 5 日 | 4214.99% | HC Wainwright & Co. | 13 美元 → 12 美元 | 维护 | 买 |
| 11/06/2020 | 978.75% | SVB Leerink | 4 美元 → 3 美元 | 维护 | 表现不佳 |
| 11/06/2020 | 5293.74% | HC Wainwright & Co. | 23 美元 → 15 美元 | 维护 | 买 |
| 05/22/2020 | 10327.9% | HC Wainwright & Co. | 33 美元 → 29 美元 | 重申 | → 购买 |
| 05/20/2020 | 1338.33% | SVB Leerink | 5 美元 → 4 美元 | 维护 | 表现不佳 |
| 2020 年 5 月 18 日 | 11766.24% | HC Wainwright & Co. | 29 美元 → 33 美元 | 维护 | 买 |
| 2020 年 6 月 5 日 | 10327.9% | HC Wainwright & Co. | 27 美元 → 29 美元 | 重申 | → 购买 |
| 2020 年 4 月 27 日 | 1697.91% | SVB Leerink | → 5 美元 | 降级 | 市场表现 → 表现不佳 |
| 04/09/2020 | 2057.5% | B of A 类证券 | → 6 美元 | 降级 | 中性 → 跑赢大盘 |
| 01/23/2020 | 3495.83% | B of A 类证券 | 7 美元 → 10 美元 | 维护 | 中立 |
| 11/19/2019 | 2776.66% | Evercore ISI 集团 | → 8 美元 | 降级 | 跑赢大盘 → 在线 |
| 2019 年 8 月 10 日 | 978.75% | 高盛 | 13 美元 → 3 美元 | 维护 | 卖出 |
| 2019 年 9 月 24 日 | — | SVB Leerink | 降级 | 跑赢大盘 → 市场表现 | |
| 08/13/2019 | 2417.08% | B of A 类证券 | 13 美元 → 7 美元 | 降级 | 买入 → 中性 |
| 2019 年 2 月 8 日 | — | 古根海姆 | 降级 | 买入 → 中性 | |
| 05/29/2019 | 5293.74% | 高盛 | 17 美元 → 15 美元 | 降级 | 中性 → 卖出 |
| 02/13/2019 | 14283.32% | HC Wainwright & Co. | → 40 美元 | 启动覆盖范围开启 | → 购买 |
| 10/31/2018 | 14283.32% | 巴克莱 | 58 美元 → 40 美元 | 维护 | 超重 |
| 10/31/2018 | 5653.33% | 摩根大通 | 71 美元 → 16 美元 | 降级 | 超重 → 中性 |
| 2018 年 9 月 25 日 | 10687.49% | Leerink Swann | → 30 美元 | 启动覆盖范围开启 | → 市场表现 |
| 02/27/2018 | 30464.55% | 巴克莱 | 105 美元 → 85 美元 | 维护 | 超重 |
| 02/27/2018 | 39454.12% | Stifel | 125 美元 → 110 美元 | 维护 | 买 |
| 02/22/2018 | — | Evercore ISI 集团 | 升级 | 盘中 → 跑赢大盘 | |
| 02/22/2018 | — | 加拿大皇家银行资本 | 升级 | 行业表现 → 跑赢大盘 |
What is the target price for Clovis Oncology (CLVS)?
克洛维斯肿瘤学（CLVS）的目标价格是多少？
The latest price target for Clovis Oncology (NASDAQ: CLVS) was reported by JP Morgan on November 10, 2022. The analyst firm set a price target for $0.00 expecting CLVS to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
摩根大通于2022年11月10日公布了克洛维斯肿瘤学（纳斯达克股票代码：CLVS）的最新目标股价。该分析公司将目标股价定为0.00美元，预计CLVS将在12个月内降至12个月内（可能下跌-100.00％）。去年有3家分析公司公布了评级。
What is the most recent analyst rating for Clovis Oncology (CLVS)?
克洛维斯肿瘤学（CLVS）的最新分析师评级是多少？
The latest analyst rating for Clovis Oncology (NASDAQ: CLVS) was provided by JP Morgan, and Clovis Oncology downgraded their underweight rating.
摩根大通对克洛维斯肿瘤学（纳斯达克股票代码：CLVS）的最新分析师评级由摩根大通提供，克洛维斯肿瘤学下调了其减持评级。
When is the next analyst rating going to be posted or updated for Clovis Oncology (CLVS)?
克洛维斯肿瘤学（CLVS）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clovis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clovis Oncology was filed on November 10, 2022 so you should expect the next rating to be made available sometime around November 10, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Clovis Oncology的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。克洛维斯肿瘤学的最新评级是在2022年11月10日发布的，因此您应该预计下一个评级将在2023年11月10日左右公布。
Is the Analyst Rating Clovis Oncology (CLVS) correct?
分析师对克洛维斯肿瘤学（CLVS）的评级是否正确？
While ratings are subjective and will change, the latest Clovis Oncology (CLVS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clovis Oncology (CLVS) is trading at is $0.28, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的克洛维斯肿瘤学（CLVS）评级已下调，目标股价为0.00美元至0.00美元。克洛维斯肿瘤学（CLVS）目前的交易价格为0.28美元，超出了分析师的预期区间。
